Picture of Biocept logo

BIOC Biocept Income Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapContrarian

Annual income statement for Biocept, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2017
December 31st
2018
December 31st
2019
December 31st
2020
December 31st
2021
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue5.073.255.5327.561.2
Cost of Revenue
Gross Profit-4.28-6.8-5.456.1223.5
Selling / General / Administrative Expenses
Research And Development
Total Operating Expenses26.227.528.642.963.7
Operating Profit-21.2-24.3-23.1-15.5-2.41
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes-21.6-24.6-25.1-17.8-2.7
Provision for Income Taxes
Net Income After Taxes-19-24.6-25.1-17.8-2.82
Net Income Before Extraordinary Items
Extraordinary Items
Net Income-21.6-24.6-25.1-17.8-2.82
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income-21.6-25.2-25.3-17.8-2.82
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-209-90.1-12.2-1.5-0.191
Dividends per Share

Or unlock with your email

Or unlock with your email